Prosecution Insights
Last updated: November 04, 2026
Application No. 18/907,350

CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF

Non-Final OA §102§112
Filed
Oct 04, 2024
Priority
Oct 06, 2023 — provisional 63/542,981
Examiner
SZNAIDMAN, MARCOS L
Art Unit
Tech Center
Assignee
Rapt Therapeutics Inc.
OA Round
1 (Non-Final)
37%
Grant Probability
At Risk
1-2
OA Rounds
1y 5m
Est. Remaining
54%
With Interview

Examiner Intelligence

Grants only 37% of cases
37%
Career Allowance Rate
478 granted / 1278 resolved
-22.6% vs TC avg
Strong +16% interview lift
Without
With
+16.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
83 currently pending
Career history
1351
Total Applications
across all art units

Statute-Specific Performance

§101
1.7%
-38.3% vs TC avg
§103
38.3%
-1.7% vs TC avg
§102
17.9%
-22.1% vs TC avg
§112
28.1%
-11.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1278 resolved cases

Office Action

§102 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION This office action is in response to applicant’s reply filed on August 27, 2026. Restrictions/Elections. Applicants’ election without traverse of Group I (Claims 1-34) in the reply filed on August 27, 2026, is acknowledged. Applicant further election of the following species: PNG media_image1.png 158 222 media_image1.png Greyscale is acknowledged. Since the above species is free of prior art, the examination was expanded to the following species: PNG media_image2.png 276 412 media_image2.png Greyscale Status of Claims Claims 1-55 are currently pending and are the subject of this office action. Claims 35-55 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected inventions, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on August 27, 2026. The elected species is encompassed by claims 1-8, 10-11 and 15-34. The expanded species is encompassed by claims: 1-3, 5, 11-12, 15-19, 21-23, 27-32 and 34. The combined claims that encompass one or two species, and consequently are under examination are: 1-8, 10-12 and 15-34. Consequently, claims 9 and 13-14 are further withdrawn. Priority The present application claims priority to provisional application No. 63/542,981 filed on 10/06/2023. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1-3, 5, 11-12, 15-19, 21-23, 27-32 and 34 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Galons et. al. (WO 2020/108407 June 4, 2020). For claims 1-3, 5, 11-12, 15-19, 21-23, 27-32 and 34, Galons teaches the following compound: PNG media_image2.png 276 412 media_image2.png Greyscale (see page 39, compound 14), Wherein: X1 is CR8, wherein R8 is H, X2 is N, X3 is CR10, wherein R10 is alkyl, X4 is CR11, wherein R11 is H, X5 is N, z1 is 1, z2 is 0, z3 is 0, z4 is 1, z5 is 2, L7 is alkylene, and R7 is OR7A, wherein R7A is H. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-8, 10-12, 15-32 and 34 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a written description rejection. Claims 1-8, 10-12, 15-32 and 34 encompass compounds of general Formula (I): PNG media_image3.png 110 294 media_image3.png Greyscale with an enormous set of different substituents. M.P.E.P. #2163 states: “An applicant shows possession of the claimed invention by describing the claimed invention with all of its limitations using such descriptive means as words, structures, figures, diagrams, and formulas that fully set forth the claimed invention….one must define a compound by ‘whatever characteristics sufficiently distinguish it’. A lack of adequate written description issue also arises if the knowledge and level of skill in the art would not permit one skilled in the art to immediately envisage the product claimed from the disclosed process”. In Ariad Pharm., Inc. v. Eli Lilly & Co., 598 F.3d 1336, 1351 (Fed. Cir. 2010) (en banc), the Federal Circuit stated that “the hallmark of written description is disclosure.” A specification adequately describes an invention when it “reasonably conveys to those skilled in the art that the inventor had possession of the claimed subject matter as of the filing date.” Id. at 1351. “A ‘mere wish or plan’ for obtaining the claimed invention is not adequate written description.” Centocor Ortho Biotech, Inc. v. Abbott Labs, 636 F.3d 1341, 1348 (Fed. Cir. 2011). The description requirement of the patent statute requires a description of an actual invention, not merely an indication of a result that one might achieve if one made that invention. See, e.g., In re Wilder, 22 USPQ 369, 372-3 (Fed. Cir. 1984) (holding that a claim was not adequately described because the specification did ‘little more than outline goals appellants hope the claimed invention achieves and the problems the invention will hopefully ameliorate’). This matter is of particular importance in the evaluation of claims drawn to a chemical genus which identifies a core compound bearing variable substituents. It has been held that “a generic claim may define the boundaries of a vast genus of chemical compounds, and yet the question may still remain whether the specification...demonstrates that the applicant has invented species sufficient to support a claim to a genus” with such breadth. Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., 94 USPQ2D 1161, 1171 (Fed. Cir. 2010). An adequate written description requires a precise definition, such as by structure, formula, chemical name, physical properties, or other properties of species falling within the genus sufficient to distinguish the genus from other materials. Id., quoting Regents of the University of California v. Eli Lilly & Co., 119 F.3d 1559, 1568 (Fed. Cir. 1997). However, merely drawing a fence around the outer limits of a purported genus is not an adequate substitute for describing a variety of materials constituting the genus and showing that one has invented a genus and not just a species. Ariad, 94 USPQ2D at 1171. 35 U.S. C. 112, first paragraph, requires a description of the invention that “clearly allow[s] persons of ordinary skill in the art to recognize that the inventor invented what is claimed.” Ariad at 1172, quoting Vas-Cath Inc. v. Mahurkar, 935 F.2d 1555 (1562-63) (Fed. Cir. 1991) (emphasis added). A sufficient disclosure is one which reasonably conveys to one having ordinary skill in the art that the inventor had possession of the claimed subject matter as of the filing date of the application in question. Vas-Cath, 935 F.2d at 1563. The description must reasonably describe the invention, not simply indicate a result which one might achieve if one actually made the invention. Eli Lilly, 119 F.3d at 1568. To properly evaluate whether an applicant has complied with the written description requirement therefore requires an analysis of whether the skilled artisan would recognize, from the description provided, the applicants were in possession of sufficient compounds representing the full breadth of diversity of the genus claimed. A description of a chemical genus will usually comprise a recitation of structural features common to the members of the genus, which features constitute a substantial portion of the members of the genus, which features constitute substantial portion of the genus. See Univ. of California vs. Eli Lilly, 43 USPQ 2d 1398, 1406 (Fed. Cir. 1997). This is analogous to enablement of a genus under section 112 first, by showing enablement of a representative number of species within the genus. A chemical genus can be adequately described if the disclosure presents a sufficient number of representative species that encompass the genus. If the genus has a substantial variance, the disclosure must describe a sufficient number of species to reflect the variation within that genus. Here, applicants have claimed an extraordinarily large genus of chemical compounds encompassed by general Formula (I). The specification discloses a list of only 38 compounds that are encompassed by the general Formula (I) of claim 1 (see pages 253-259 of the specification) despite claim 1 encompassing millions of compounds. z1 is always 2 and R3 is Cl, F or Me, R1 is always Me and R2 is always H, R4 is always H, X1 is always CH X2 is always N, X3 is CH or N X4 is always CH X5 is CH or N The size of the genus claimed is phenomenal, against which the applicants have offered evidence of being in possession of only 38 compounds (see pages 253-259 of the specification). This small set of compounds cannot be viewed as being reasonably representative of the genus of compounds of Formula I in its claimed scope because no readily apparent combination of identifying characteristics is provided, other than the disclosure of those specific species as examples of the claimed genus, and in no way either represent the breadth of variable moieties which applicants have claimed, nor permit the skilled artisan to recognize that such claim breadth was actually in the applicants possession as of the time of filing the instant application. Given the broad scope of the claimed subject matter, Applicant has not provided sufficient written description that would allow the skilled in the art to recognize that Applicant was in possession of most the compounds of the above general Formula I claimed. NOTE: In order to overcome this rejection, it is suggested that Applicant amends the above claims according to something like Formula VIIIb: PNG media_image4.png 144 272 media_image4.png Greyscale Wherein: R32 and R33 are Cl, F or Me, R1 is Me, R2 is H, R4 is H, X3 is N or CH X4 is CH, and Z4 is 1 Claim Objections Claim 33 is objected to as being dependent upon a rejected base claim but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Conclusion No claims are allowed. Correspondence Any inquiry concerning this communication or earlier communications from the examiner should be directed to MARCOS L SZNAIDMAN whose telephone number is (571)270-3498. The examiner can normally be reached Flexing M-F 7 AM-7 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amy L. Clark can be reached on 571 272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MARCOS L SZNAIDMAN/ Primary Examiner, Art Unit 1628 August 28, 2026
Read full office action

Prosecution Timeline

Oct 04, 2024
Application Filed
Oct 06, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12773419
PHARMACOLOGICAL AGENTS FOR TREATING CONDITIONS OF THE EYE
3y 5m to grant Granted Oct 27, 2026
Patent 12758502
COMPOSITIONS AND METHODS OF USE
5y 8m to grant Granted Oct 13, 2026
Patent 12751949
Crystalline Forms of a BTK Inhibitor
4y 10m to grant Granted Oct 06, 2026
Patent 12751944
Methods and Compositions for Treating Fungal Infections
3y 11m to grant Granted Oct 06, 2026
Patent 12734146
Cobalt-Porphyrin Complexes for the Inactivation of the Biological Activity of Opioids
4y 6m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
37%
Grant Probability
54%
With Interview (+16.1%)
3y 6m (~1y 5m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1278 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month